Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

Novartis considers filings for PI3K drug in breast cancer

Novartis considers filings for PI3K drug in breast cancer

Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... Approximately 40% of HR+ advanced breast cancer patients have PIK3CA

Latest news

More from news
Approximately 1 fully matching, plus 145 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810, is

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... Palbociclib, which is the result of an early

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics